2021.12.28
On December 20, 2021, the Nasdaq listed company Legend Biotech Corporation (“Legend Biotech” with stock code LEGN), successfully completed its follow-on public offering of 8,615,575 American Depositary Shares (“ADSs”), inclusive of the over-allotment, at the price of USD 40 per ADS, raising funds of approximately USD 345 million.
Legend Biotech is a clinical-stage biopharmaceutical company dedicated to developing novel cell therapies for tumors and other indications in America, China and Europe. Its flagship product candidate is LCAR-B38M/JNJ-4528 which was jointly developed by Legend Biotech and Janssen Biotech, Inc., a pharmaceutical company controlled by Johnson & Johnson. It is a chimeric antigen receptor (CAR) T-cell immunotherapy treatment for multiple myeloma.
In June 2020, JunHe assisted Legend Biotech in its initial offering of ADSs and its listing on the Nasdaq Global Select Market. In this project, JunHe continued to act as the Chinese legal counsel to Legend Biotech and advised it on its follow-on public offering from the perspective of PRC laws. Specifically, JunHe conducted legal due diligence on the Chinese subsidiaries of Legend Biotech, drafted, reviewed, and revised the application and offering documents regarding the follow-on public offering, and issued Chinese legal opinions.
The leading partners of this project were WANG, Yi and LI, Chenliang .
